(Q38185176)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Prostate cancer biomarkers: an update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

0 references

1 reference

Felix Campos-Juanatey

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

Javier Romero Otero

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Borja Garcia Gomez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Karim A Touijer

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

publication date

1 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

252-260

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

7 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

7 January 2021

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Biomarker discovery and validation: technologies and integrative approaches

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Challenges of cancer biomarker profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Running before we can walk?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

New cancer biomarkers deriving from NCI early detection research.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

PCA3: a molecular urine assay for predicting prostate biopsy outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Predicting prostate cancer risk through incorporation of prostate cancer gene 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Immediate impact of ultrasound-guided prostate biopsies on PCA3 score

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Free prostate-specific antigen in serum is becoming more complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

"BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Intact and internally cleaved free prostate-specific antigen in patients with prostate cancer with different pathologic stages and grades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Recurrent gene fusions in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

TMPRSS2-ERG Fusion Prostate Cancer: An Early Molecular Event Associated With Invasion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

A multiplex model of combining gene-based, protein-based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Enhanced Discrimination of Benign from Malignant Prostatic Disease by Selective Measurements of Cleaved Forms of Urokinase Receptor in Serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Prognostic and predictive value of intact and cleaved forms of the urokinase plasminogen activator receptor in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Selective photodetection and photodynamic therapy for prostate cancer through targeting of proteolytic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Prognostic value of combined "triple"-reverse transcription-PCR analysis for prostate-specific antigen, human kallikrein 2, and prostate-specific membrane antigen mRNA in peripheral blood and lymph nodes of prostate cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Treatment of PC3 prostate cancer cells with mitoxantrone, etoposide, doxorubicin and carboplatin induces distinct alterations in the expression of kallikreins 5 and 11.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Early identification of individuals with prostate cancer in negative biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

EPCA-2: a highly specific serum marker for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

POINT: EPCA-2: A promising new serum biomarker for prostatic carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.017

10.1016/J.UROLONC.2013.09.017

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24495450%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference